secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2024-04-04T23:59:59+00:00
Accession:  0001171843-24-001830
Event type: litigation
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus Biopharma Announces Claim Construction Ruling in Patent Lawsuit Against Moderna
--------------------------------------------------------------------------------

- Court agreed with Arbutus and Genevant that the claimed mol. % ranges for total lipid ('069 patent) are not limited to 'finished' particles and include standard variation.
- Court held no limitation on mol. % of the claimed cationic lipid with protonatable tertiary amine ('378 patent) as argued by plaintiffs.
- Court construed 'fully encapsulated' mRNA ('651 patent) to mean mRNA wholly contained inside lipid vesicles, distinct from partial encapsulation.
- Arbutus and Genevant seek fair compensation for Moderna's use of LNP technology in its COVID-19 vaccine MRNA-1273 without which the vaccine would not have succeeded.
- Michael J. McElhaugh, Interim CEO, stated the company is pleased with the ruling and remains committed to protecting its intellectual property.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324001830/0001171843-24-001830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324001830/f8k_040424.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-001830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer